Rose M. Parkinson, Ph.D.
Affiliations: | 2012 | Johns Hopkins University, Baltimore, MD |
Area:
ImmunologyGoogle:
"Rose Parkinson"Parents
Sign in to add mentor| Jonathan Powell | grad student | 2012 | Johns Hopkins | |
| (Egr3 induces a Th17 response and systemic tissue inflammation by promoting the development of gamma delta T cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wang J, Gai J, Zhang T, et al. (2024) Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Science Advances. 10: eadk1827 |
| Baretti M, Murphy AG, Zahurak M, et al. (2023) A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer. Clinical Epigenetics. 15: 74 |
| Li K, Tandurella JA, Gai J, et al. (2022) Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell |
| Naidoo J, Schreck KC, Hu C, et al. (2020) Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response. Journal of Clinical Oncology. 38: e14506-e14506 |
| Murphy AG, Walker R, Lutz ER, et al. (2019) Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer. Journal of Clinical Oncology. 37: 591-591 |
| Osipov A, Sugar E, Ferguson A, et al. (2019) Abstract CT164: A Phase II clinical trial of GVAX pancreas vaccine (with Cyclophosphamide) in combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC) Cancer Research. 79 |
| Lee V, Rodriguez C, Shupe E, et al. (2017) Phase II study of GM-CSF secreting allogeneic pancreatic cancer vaccine (GVAX) with PD-1 blockade antibody and stereotactic body radiation therapy (SBRT) for locally advanced pancreas cancer (LAPC). Journal of Clinical Oncology. 35: TPS4154-TPS4154 |
| Parkinson RM, Collins SL, Horton MR, et al. (2014) Egr3 induces a Th17 response by promoting the development of γδ T cells. Plos One. 9: e87265 |
| Le DT, Laheru DA, Purtell K, et al. (2014) A phase II trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 32: 4135-4135 |
| Patel RK, Ko AH, Onners B, et al. (2014) A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer. Journal of Clinical Oncology. 32: TPS4160-TPS4160 |